Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 02, 2020 | IVERIC bio to Present at the Jefferies 2020 Healthcare Conference May 27, 2020 | IVERIC bio Reports First Quarter 2020 Operational Highlights and Financial Results May 06, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 04, 2020 | IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 | IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 02, 2020 | IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 | IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 03, 2020 | Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 |
IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 |
IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 |
IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 |
Press Releases News Year None202020192018201720162015201420132012 IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Jun 02, 2020 | IVERIC bio to Present at the Jefferies 2020 Healthcare Conference May 27, 2020 | IVERIC bio Reports First Quarter 2020 Operational Highlights and Financial Results May 06, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 04, 2020 | IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 | IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 | IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Apr 02, 2020 | IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 | IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 | IVERIC bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 03, 2020 | Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
IVERIC bio to Report First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Apr 28, 2020 |
IVERIC bio Announces Fast Track Designation from U.S. FDA for Zimura® for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Apr 03, 2020 |
IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer Mar 23, 2020 |
IVERIC bio Provides Update on the Initiation of the Second Pivotal Clinical Trial Enrollment for Zimura® in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Mar 18, 2020 |
